VRTX
VERTEX PHARMACEUTICALS INC / MA
Latest Form 4:Sale$800KbyMcKechnie Duncan (EVP, Chief Commercial Officer) · filed Jul 7, 2026
VERTEX PHARMACEUTICALS INC / MA (VRTX) has 96 SEC Form 4 filings (190 transaction rows) in the rolling window, disclosed by 13 distinct insiders. Most recent filing: Aug 31, 2026.
The most active filer is EVP and CMO Bozic Carmen with 10 filings. Insiders have net sold $16.5M over the trailing 6 months.
- Industry:Biotechnology
- CEO:Reshma Kewalramani
- Employees:6,400
- HQ:Boston, MA, US
- IPO:1991-07-24
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$158.4M
reported sales (SEC code S)
Unique Insiders
13
in the rolling window
Market Cap
$138.0B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
McKechnie DuncanFirst in 4 months | EVP, Chief Commercial Officer | Sale | 1,541 | $800K | Jul 7 | SEC ↗ |
Tatsis OuraniaFirst in 4 months | EVP, Chief Reg. & Quality Off. | Sale | 1,500 | $787K | Jul 7 | SEC ↗ |
| EVP and Chief Legal Officer | Sale | 828 | $416K | Jul 6 | SEC ↗ | |
| EVP and CMO | Sale | 596 | $288K | Jun 30 | SEC ↗ | |
| EVP and CMO | Sale | 1,020 | $471K | Jun 23 | SEC ↗ | |
| EVP and CMO | Sale | 4,062 | $1.8M | Jun 17 | SEC ↗ | |
| EVP and CMO | Sale | 1,745 | $785K | Jun 9 | SEC ↗ | |
| EVP and Chief Legal Officer | Sale | 828 | $364K | Jun 3 | SEC ↗ | |
| EVP and CMO | Sale | 1,974 | $888K | Jun 2 | SEC ↗ | |
| EVP and CMO | Sale | 1,354 | $614K | May 19 | SEC ↗ | |
| EVP, Chief Scientific Officer | Sale | 33 | $15K | May 19 | SEC ↗ | |
| EVP and CMO | Sale | 6,988 | $3.1M | May 14 | SEC ↗ | |
| Director | Sale | 318 | $135K | May 5 | SEC ↗ | |
| EVP and Chief Legal Officer | Sale | 1,104 | $469K | May 5 | SEC ↗ | |
| EVP and Chief Legal Officer | Sale | 978 | $439K | Apr 3 | SEC ↗ | |
| EVP and CMO | Sale | 2,329 | $1.1M | Mar 31 | SEC ↗ | |
| EVP and CMO | Sale | 2,329 | $1.1M | Mar 17 | SEC ↗ | |
| EVP, Chief Commercial Officer | Sale | 2,633 | $1.3M | Mar 13 | SEC ↗ | |
| EVP, Chief Commercial Officer | Sale | 2,437 | $1.2M | Mar 6 | SEC ↗ | |
Liu JoyFirst filing | EVP and Chief Legal Officer | Sale | 892 | $442K | Mar 4 | SEC ↗ |
Kewalramani ReshmaFirst filing | CEO & President | Sale | 40,000 | $19.7M | Mar 3 | SEC ↗ |
Bozic CarmenFirst filing | EVP and CMO | Sale | 2,329 | $1.1M | Mar 3 | SEC ↗ |
| SVP & Chief Accounting Officer | Sale | 357 | $173K | Mar 2 | SEC ↗ | |
McKechnie DuncanFirst filing | EVP, Chief Commercial Officer | Sale | 4,910 | $2.4M | Feb 26 | SEC ↗ |
| EVP, Chief Scientific Officer | Sale | 620 | $302K | Feb 26 | SEC ↗ | |
| EVP and Chief Legal Officer | Sale | 945 | $460K | Feb 26 | SEC ↗ | |
| EVP Chief Patient & Ext Af Off | Sale | 1,846 | $898K | Feb 26 | SEC ↗ | |
| EVP, Chief Reg. & Quality Off. | Sale | 260 | $126K | Feb 26 | SEC ↗ | |
| EVP, Chief Technical Ops. Off. | Sale | 668 | $325K | Feb 26 | SEC ↗ | |
| SVP & Chief Accounting Officer | Sale | 223 | $108K | Feb 26 | SEC ↗ | |
Sachdev AmitFirst filing | EVP Chief Patient & Ext Af Off | Sale | 58,613 | $27.5M | Feb 23 | SEC ↗ |
| EVP, Chief Scientific Officer | Sale | 2,437 | $1.2M | Feb 19 | SEC ↗ | |
| EVP, Chief Scientific Officer | Sale | 1,182 | $560K | Feb 19 | SEC ↗ | |
| SVP & Chief Accounting Officer | Sale | 1,557 | $762K | Feb 19 | SEC ↗ | |
| SVP & Chief Accounting Officer | Sale | 638 | $302K | Feb 19 | SEC ↗ | |
| EVP and Chief Legal Officer | Sale | 2,476 | $1.2M | Feb 19 | SEC ↗ | |
| EVP and Chief Legal Officer | Sale | 1,244 | $589K | Feb 19 | SEC ↗ | |
| EVP, Chief Reg. & Quality Off. | Sale | 609 | $298K | Feb 19 | SEC ↗ | |
| EVP, Chief Reg. & Quality Off. | Sale | 368 | $174K | Feb 19 | SEC ↗ | |
| EVP, Chief Technical Ops. Off. | Sale | 2,031 | $994K | Feb 19 | SEC ↗ | |
| EVP, Chief Technical Ops. Off. | Sale | 817 | $387K | Feb 19 | SEC ↗ | |
| EVP, Chief Reg. & Quality Off. | Sale | 1,500 | $750K | Feb 18 | SEC ↗ | |
| EVP and Chief Legal Officer | Sale | 988 | $493K | Feb 18 | SEC ↗ | |
Bhatia Sangeeta N.First filing | Director | Sale | 266 | $133K | Feb 18 | SEC ↗ |
| EVP, Chief Reg. & Quality Off. | Sale | 466 | $215K | Feb 12 | SEC ↗ | |
| EVP and Chief Legal Officer | Sale | 1,925 | $886K | Feb 12 | SEC ↗ | |
Ambrose KristenFirst filing | SVP & Chief Accounting Officer | Sale | 1,376 | $634K | Feb 12 | SEC ↗ |
| EVP, Chief Technical Ops. Off. | Sale | 1,751 | $806K | Feb 12 | SEC ↗ | |
Bunnage Mark E.First filing | EVP, Chief Scientific Officer | Sale | 2,021 | $931K | Feb 12 | SEC ↗ |
| EVP, Chief Reg. & Quality Off. | Sale | 4,500 | $2.1M | Jan 9 | SEC ↗ | |
| EVP, CO & FO | Sale | 9,532 | $4.4M | Jan 8 | SEC ↗ | |
| Executive Chairman | Sale | 63,781 | $28.7M | Dec 5 | SEC ↗ | |
WAGNER CHARLES F JRFirst filing | EVP, CO & FO | Sale | 14,000 | $6.4M | Dec 5 | SEC ↗ |
| EVP and Chief Legal Officer | Sale | 347 | $156K | Dec 5 | SEC ↗ | |
Tatsis OuraniaFirst filing | EVP, Chief Reg. & Quality Off. | Sale | 4,500 | $2.0M | Dec 5 | SEC ↗ |
Atkinson Edward Morrow IIIFirst filing | EVP, Chief Technical Ops. Off. | Sale | 2,500 | $1.1M | Nov 19 | SEC ↗ |
LEIDEN JEFFREY MFirst filing | Executive Chairman | Sale | 19,688 | $8.7M | Nov 17 | SEC ↗ |
LEIDEN JEFFREY MFirst filing | Executive Chairman | Sale | 53,604 | $23.6M | Nov 17 | SEC ↗ |
Biller JonathanFirst filing | EVP and Chief Legal Officer | Sale | 694 | $281K | Oct 3 | SEC ↗ |
Congress trading VRTX
See timeline →- DRep. Ro KhannaPurchase$1,001 - $15,0002026-04-13
STOCK Act disclosures are filed up to 45 days after the trade. Amount is a disclosed range, not an exact figure.
Related companies
VERTEX PHARMACEUTICALS INC / MA is in the Healthcare sector.